ArticleCureus2026
Clinico-Radiological Profile, Management Strategies, and Survival Outcomes in Medulloblastoma: A Retrospective Study From a Tertiary Care Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Medulloblastoma is the most common malignant pediatric brain tumor. While survival outcomes have improved in high-income countries, results in low- and middle-income countries (LMICs) remain limited by delayed presentation, socioeconomic constraints, and incomplete adjuvant therapy. Hence, this study aimed to evaluate the clinico-radiological profile, management strategies, and prognostic factors influencing survival in patients with medulloblastoma treated at a tertiary neurosurgical center. Methodology A total of 56 patients with histologically confirmed medulloblastoma operated on between January 2019 and March 2024 were retrospectively analyzed. Clinical, radiological, surgical, and treatment data were collected. Survival was estimated using Kaplan-Meier analysis and compared using the log-rank test. Multivariate Cox proportional hazards modeling was performed using a parsimonious model. Results The mean age was 9.7 ± 4.3 years (range = 3-28), with 40 (71%) males. Most tumors were vermian in location (50, 89.3%) and ≥50 mm in size (38, 67.9%). Gross total resection was achieved in 47 (83.9%) patients. Completion of adjuvant therapy was associated with improved survival (median 23 vs. 4 months; p < 0.0001). Conclusions In this LMIC cohort, completion of postoperative adjuvant therapy (craniospinal radiotherapy followed by chemotherapy) emerged as an important modifiable factor influencing survival. The association between ataxia and improved survival reflects earlier detection rather than biological advantage. Strengthening postoperative radiotherapy compliance and multidisciplinary coordination is essential to improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.